Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501).
Rebecca A SnyderTyler J ZemlaQian ShiDiana SegoviaSyed A AhmadEileen M O'ReillyJoseph M HermanMatthew H G KatzPublished in: Annals of surgical oncology (2024)
Clinicaltrials.gov identifier: NCT02839343.
Keyphrases
- clinical trial
- locally advanced
- minimally invasive
- rectal cancer
- coronary artery bypass
- patients undergoing
- lymph node
- squamous cell carcinoma
- phase ii
- surgical site infection
- study protocol
- open label
- liver metastases
- double blind
- radiation therapy
- percutaneous coronary intervention
- mesenchymal stem cells
- cell therapy